NovaBridge Biosciences NBP
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.21
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $632.0K | -$1.6M | $13.8M | $236.4M | $4.3M | — | — |
| Cost of revenue | — | — | — | $3.9M | $7.3M | — | — | — | — |
| Gross profit | — | — | — | -$5.5M | $6.5M | — | — | — | — |
| R&D | $62.9M | $21.8M | $21.4M | $22.5M | $190.3M | $150.9M | $120.7M | — | — |
| SG&A | $31.4M | $29.7M | $28.2M | $29.0M | $141.2M | $61.7M | $94.0M | — | — |
| Total operating expenses | $94.3M | $51.4M | $72.6M | $51.5M | — | — | — | — | — |
| Operating income | -$94.3M | -$51.4M | -$72.0M | -$53.1M | — | — | — | — | — |
| Interest expense | — | — | $102.0K | $1.0K | $0 | $147.0K | $430.0K | — | — |
| Pre-tax income | -$88.3M | -$49.7M | -$82.2M | -$141.1M | -$366.4M | $74.0M | -$208.6M | — | — |
| Income tax | $0 | $0 | $0 | $103.0K | $495.0K | $1.9M | — | — | — |
| Net income | -$46.3M | -$22.2M | -$207.7M | -$371.1M | -$365.9M | $72.2M | -$208.6M | — | — |
| EPS, basic | -0.21 | -0.12 | -1.09 | -1.96 | -2.09 | 0.54 | -28.90 | — | — |
| EPS, diluted | -0.21 | -0.12 | -1.09 | -1.96 | -2.09 | 0.46 | -28.90 | — | — |
| Shares, diluted (wtd. avg.) | 220.3M | 186.7M | 191.4M | 189.8M | 174.7M | 157.2M | 7.4M | 6.5M | 5.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $210.6M | $68.3M | $291.5M | $475.4M | $552.7M | $746.8M | $182.9M | $241.5M | — |
| Short-term investments | $210.0K | $105.1M | $20.2M | $34.1M | $118.2M | $4.8M | $4.6M | — | — |
| Receivables | — | — | — | $0 | $5.2M | $20.0M | — | — | — |
| Inventory | — | — | — | $0 | $4.3M | — | — | — | — |
| Total current assets | $217.5M | $176.7M | $329.9M | $525.8M | $750.4M | $819.0M | $195.5M | — | — |
| Property, plant and equipment | $140.0K | $201.0K | $1.8M | $8.8M | $7.2M | $3.9M | $4.3M | — | — |
| Goodwill | — | — | — | $23.6M | $25.5M | $24.9M | $23.4M | — | — |
| Other intangibles | — | — | $16.6M | $17.2M | $18.8M | $18.5M | $22.8M | — | — |
| Total assets | $260.5M | $212.7M | $368.9M | $590.6M | $878.9M | $970.7M | $249.6M | — | — |
| Accounts payable | $16.8M | $7.5M | $7.8M | $102.4M | $93.1M | $85.9M | $39.3M | — | — |
| Short-term debt | — | — | $4.2M | $2.7M | — | — | $7.2M | — | — |
| Total current liabilities | $26.9M | $8.5M | $58.1M | $109.9M | $97.9M | $88.3M | $84.5M | — | — |
| Total liabilities | $29.6M | $11.5M | $126.3M | $168.7M | $163.5M | $108.3M | $96.0M | — | — |
| Retained earnings | -$1.33B | -$1.29B | -$1.26B | -$994.9M | -$683.4M | -$310.1M | -$358.3M | — | — |
| Total equity | $230.9M | $201.2M | $242.6M | $417.8M | $715.1M | $862.4M | -$292.3M | — | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.6M | -$52.7M | -$72.7M | -$49.6M | -$152.7M | $66.4M | -$124.7M | — | — |
| Depreciation and amortisation | $68.0K | $261.0K | $475.0K | $200.0K | $2.2M | $2.0M | $1.4M | — | — |
| Stock-based compensation | $6.0M | -$1.9M | $10.2M | $13.1M | $95.5M | $75.6M | $52.7M | — | — |
| Capital expenditure | $7.0K | $48.0K | $164.0K | $2.1M | $4.7M | $1.2M | $1.8M | — | — |
| Investing cash flow | $105.0M | -$136.0M | -$15.2M | -$5.2M | -$114.1M | -$30.9M | $30.5M | — | — |
| Financing cash flow | $57.7M | -$335.0K | -$8.2M | $3.9M | $93.2M | $527.3M | $21.9M | — | — |
| Buybacks | — | $335.0K | $8.6M | $3.0M | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001778016-26-000006.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Buybacks
- Depreciation and amortisation
- Receivables
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Buybacks | — | — | — | — | — | $3.0M | $8.6M | $335.0K | — |
| Depreciation and amortisation | — | — | $1.4M | $2.0M | $2.2M | $200.0K | $475.0K | $261.0K | $68.0K |
| Receivables | — | — | — | $20.0M | $5.2M | $0 | — | — | — |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |